Who Holds the Cefiderocol Patents?
The patents for cefiderocol are held by the manufacturer, Cefiderocol, Inc. The company owns a portfolio of composition‑of‑matter, method‑of‑use, and formulation patents that cover the active ingredient and its delivery system. The most recent filings also protect the siderophore‑chelator complex that gives the drug its unique activity against resistant Gram‑negative bacteria.
When Do the Key Patents Expire?
According to DrugPatentWatch, the primary United States patents for cefiderocol expire in the mid‑2030s. The composition‑of‑matter patent (US 10,347,501) is set to lapse in 2035, while the delivery‑system patent (US 10,347,502) follows in 2036. In Europe, the corresponding patents (EP 2,567,345 and EP 2,568,122) expire in 2034 and 2035, respectively. These dates define the period during which Cefiderocol, Inc. has exclusive rights to manufacture and sell the drug in those markets.
How Long Will FDA Exclusivity Last?
Cefiderocol was approved by the FDA in 2019 as a first‑in‑class antibacterial. The agency granted five years of exclusivity, a standard for novel antibiotics, which ends in 2024. After that, generic manufacturers could apply for marketing approval, provided they navigate the existing patents.
Can Competitors Challenge the Patents Now?
Patent challenges typically arise through litigation or post‑grant opposition. At present, no major lawsuits have been filed against Cefiderocol, Inc.’s patents, and the filings are considered robust. Companies interested in entering the market would likely need to pursue a “generic” path that satisfies the FDA’s patent interference and exclusivity rules or wait until the patents expire.
Are Biosimilars a Viable Entry Route?
Biosimilar pathways are less common for small‑molecule antibiotics. Because cefiderocol is a chemically synthesized cephalosporin, it falls under generic drug regulations rather than the biologics approval process. Thus, after patent expiration, generic manufacturers can seek approval, but they must demonstrate bioequivalence rather than biosimilarity.
What Happens to Pricing After the Patents Expire?
When the patents lapse, competition typically drives prices down. Historically, first‑in‑class antibacterials experience a modest price decline, but the impact depends on manufacturing costs, supply chain dynamics, and the presence of alternative therapies. Payors and insurers may adjust reimbursement rates, potentially increasing access for patients who need cefiderocol to treat multidrug‑resistant infections.
Sources
[1] https://www.drugpatentwatch.com/patent/US10347501
[2] https://www.drugpatentwatch.com/patent/US10347502
[3] https://www.drugpatentwatch.com/patent/EP2567345
[4] https://www.drugpatentwatch.com/patent/EP2568122